Immunotherapy for melanoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Dermatology

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/EDM.11.80
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

  2012cited by this paper
• Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses?

  2012cited by this paper
• Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.

  2011cited by this paper
• Ipilimumab: A Novel Treatment for Metastatic Melanoma

  2011cited by this paper
• PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

  2011cited by this paper
• A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF-β1

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Beyond ipilimumab: new approaches target the immunological synapse.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

  2011cited by this paper
• Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?

  2011cited by this paper
• Chemokines and cancer: a fatal attraction.

  2011cited by this paper
• Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells

  2011cited by this paper
• Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies

  2011cited by this paper
• A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

  2011cited by this paper
• CD1a and CD1d Genes Polymorphisms in Breast, Colorectal and Lung Cancers

  2011cited by this paper
• Chemokines in cancer related inflammation.

  2011cited by this paper
• New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response

  2011cited by this paper
• Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis

  2011cited by this paper
• Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Amgen spikes interest in live virus vaccines for hard-to-treat cancers

  2011cited by this paper
• Re-inventing intratumoral immunotherapy for melanoma.

  2011cited by this paper
• Targeted therapies in metastatic melanoma: toward a clinical breakthrough?

  2010cited by this paper
• CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

  2010cited by this paper
• Functional and clinical relevance of chondroitin sulfate proteoglycan 4.

  2010cited by this paper
• Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines

  2010cited by this paper
• Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

  2010cited by this paper
• CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893

  2010cited by this paper
• A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

  2010cited by this paper
• Cancer and Inflammation: Promise for Biologic Therapy

  2010cited by this paper
• Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

  2010cited by this paper
• Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

  2010cited by this paper
• Clinical development of the anti-CTLA-4 antibody tremelimumab.

  2010cited by this paper
• The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

  2010cited by this paper
• Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*

  2010cited by this paper
• Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.

  2010cited by this paper
• Electroporation gene therapy preclinical and clinical trials for melanoma.

  2010cited by this paper
• Cancer esearch oenvironment and Immunology ctive Depletion of Foxp 3 + Regulatory T Cells roves Effective Therapeutic Vaccination R inst Established Melanoma

  2010cited by this paper
• Establishment of stable cell lines for personalized melanoma cell vaccine

  2010cited by this paper
• High response rate after intratumoral treatment with interleukin‐2

  2010cited by this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Clinical dritic Cell Vaccination in Combination with Anti-CD 25 oclonal Antibody Treatment : A Phase I / II Study in R astatic Melanoma Patients

  2010cited by this paper
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009cited by this paper
• Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

  2009cited by this paper
• Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

  2009cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

  2009cited by this paper
• The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

  2009cited by this paper
• Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

  2009cited by this paper
• The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

  2009cited by this paper
• Intracellular detection and immune signaling pathways of DNA vaccines

  2009cited by this paper
• Bevacizumab: current indications and future development for management of solid tumors

  2009cited by this paper
• Completely regressed cutaneous melanocytic lesion revisited.

  2009cited by this paper
• DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer.

  2009cited by this paper
• Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

  2009cited by this paper
• Increased survival from stage IV melanoma associated with fewer regulatory T Cells.

  2009cited by this paper
• Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.

  2009cited by this paper
• Decreased TNF-α synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging

  2009cited by this paper
• Multipeptide vaccination in cancer patients

  2009cited by this paper
• Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

  2009cited by this paper
• Adoptive cell therapy for the treatment of patients with metastatic melanoma.

  2009cited by this paper
• Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

  2009cited by this paper
• OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

  2009cited by this paper
• Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• The role of OX40-mediated co-stimulation in T-cell activation and survival.

  2009cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Topical imiquimod and intralesional interleukin‐2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

  2008cited by this paper
• Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

  2008cited by this paper
• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

  2008cited by this paper
• Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

  2008cited by this paper
• Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

  2008cited by this paper
• Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood

  2008cited by this paper
• The biology of interleukin-2.

  2008cited by this paper
• Polarized immune responses differentially regulate cancer development

  2008cited by this paper
• Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.

  2008cited by this paper
• Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

  2008cited by this paper
• Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

  2008cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

  2008cited by this paper
• Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

  2008cited by this paper
• Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

  2008cited by this paper
• Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma.

  2008cited by this paper
• Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

  2008cited by this paper
• Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma

  2008cited by this paper
• OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

  2008cited by this paper
• First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

  2008cited by this paper
• Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1

  2008cited by this paper
• Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

  2008cited by this paper

• No citing papers are available for this paper.